GenMark Diagnostics, Inc. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (NASDAQ:GNMK) represented a move of 1.17 percent or $-0.05 per share and closed its previous day trading session at $5.21. 239333 Shares were traded in the last trading session with an Average Volume of 400.29 Million Shares. The stock currently has a Market Capitalization of 288.22 Million.
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor(r) XT-8 system is the second generation in GenMark Dx’s eSensor(r) platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
The stock traded between $3.98 and $8.81 over 1-Year time period showing its price to sales ratio of 4.28. GenMark Diagnostics, Inc. (NASDAQ:GNMK) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-10.22 and 200-Day Simple Moving Average of $-17.9. Its Price to Free Cash Flow is 0 and Price to Book of 6.95.
Analyst’s recommended the stock as 1.5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, GenMark Diagnostics, Inc. (NASDAQ:GNMK) reported its Actual EPS of $-0.2/share. The analysts offering Earnings Estimates for the company were believing that GenMark Diagnostics, Inc. could bring EPS of $-0.2/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
Northern Dynasty Minerals, Ltd. (NYSE:NAK)
In the last trading session, Northern Dynasty Minerals, Ltd. (NYSE:NAK) added its value by 0.4% closing at the price of $0.76. The stock currently has market capitalization of 235.4 Million, with average volume of 982.11 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Northern Dynasty Minerals, Ltd. (NYSE:NAK) is showing beta of 0.13. This particular value of beta suggests that Northern Dynasty Minerals, Ltd. (NYSE:NAK) has historically moved 13% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Northern Dynasty Minerals, Ltd. (NYSE:NAK) is at $-0.04.
The stock currently has RSI of 66.97. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Northern Dynasty owns the rights to purchase 100% of the Pebble gold-copper-molybdenum porphyry deposit, where successful drilling programs have delineated an Inferred Mineral Resource. Northern Dynasty is the largest gold deposit and one of the largest copper deposits in North America.
Northern Dynasty Minerals, Ltd. (NYSE:NAK) topped its 52-week high price of $2.300 on 12/18/17 and 52-Week Low Price of $0.430 on 05/29/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.39% and monthly volatility of 9.55% respectively.